Steven James, MD
Chief Medical Officer & Co-Founder

Steven P. James, MD, MBA is a veteran of over three decades in pharmaceutical research and medical education and is a Lifetime Fellow of the American Board of Psychiatry and Neurology and the American Board of Sleep Medicine. In the pharmaceutical industry, Dr. James has held positions of senior leadership and contributed to the development and educational strategies for several major products including Fluoxetine (Prozac), Duloxetine (Cymbalta), Interferon beta-1a (Rebif) and Botulinum Toxin (Botox). Dr. James graduated from the University of Kentucky College of Medicine followed by residency training in psychiatry at the New York-Presbyterian Hospital, Cornell and additional training as a Hollister fellow in psychopharmacology at Stanford University School of Medicine. He was a research fellow at the National Institute of Mental Health (NIMH) for three years followed by an appointment to the research and teaching faculty at the University of Pennsylvania School of Medicine. Over the course of his career, Dr. James has presented to Over the course of his career, Dr. James has presented to professional and lay audiences on mental health issues and his research interests. He has appeared on ABC’s Good Morning America, delivered scientific presentations at medical congresses in North America, Europe and Asia, and has published in scientific journals and medical books. He has recently written the book A Clinician’s Guide to Cannabinoid Science published by Cambridge University Press. Currently he serves as an Adjunct Assistant Professor of Psychiatry at the University of California, San Diego (UCSD).